Restricted accessResearch articleFirst published online 2025-6
Identifying the mediating role of brain atrophy on the relationship between DNA damage repair pathway and Alzheimer's disease: A Mendelian randomization analysis and mediation analysis
DNA damage and repair (DDR) and structural atrophies in different brain regions were recognized as critical factors in the onset of Alzheimer's disease (AD).
Objective
We utilized Mendelian randomization (MR) to examine the causal effects of the DDR-related molecular traits on AD and the potential mediating roles of different brain region volumes.
Methods
In primary analysis, we utilized public genome-wide association studies of AD and summary data from existing molecular traits datasets, including gene expression, DNA methylation, and protein levels quantitative trait loci (eQTL, mQTL, and pQTL) in both blood and brain to examine their causal associations by summary-data-based MR analysis and additional five two-sample MR methods. Subsequently, mediation analysis explored the potential mediate roles of 13 imaging-derived brain volume phenotypes in the associations between the DDR pathways and AD through a network MR design.
Results
We found that the volumes of the right thalamus proper and global cerebral white matter mediated the causal pathways from EGFR to AD and relatively weak mediation effects of the right lateral ventricle volume in the causal pathways involving CHRNE, DNTT, and AD.
Conclusions
We identified causal relationships among DDR pathways, specific brain region volumes, and AD. Monitoring the molecular traits of these DDR-related genes and developing targeted drugs may help detect and interrupt the early progression of AD.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer's disease. Lancet2021; 397: 1577–1590.
2.
TiwariVWilsonDM. DNA Damage and associated DNA repair defects in disease and premature aging. Am J Hum Genet2019; 105: 237–257.
3.
LinXKapoorAGuY, et al.Contributions of DNA damage to Alzheimer's disease. Int J Mol Sci2020; 21: 1666.
4.
KrumanIIWerstoRPCardozo-PelaezF, et al.Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron2004; 41: 549–561.
5.
MadabhushiRPanLTsaiL-H. DNA Damage and its links to neurodegeneration. Neuron2014; 83: 266–282.
6.
Bradley-WhitmanMATimmonsMDBeckettTL, et al.Nucleic acid oxidation: an early feature of Alzheimer's disease. J Neurochem2014; 128: 294–304.
7.
BaytasIM. Predicting progression from mild cognitive impairment to Alzheimer's dementia with adversarial attacks. IEEE J Biomed Health Inform2024; 28: 3750–3761.
8.
BakkourAMorrisJCWolkDA, et al.The effects of aging and Alzheimer's disease on cerebral cortical anatomy: specificity and differential relationships with cognition. Neuroimage2013; 76: 332–344.
9.
DickersonBCBakkourASalatDH, et al.The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex2009; 19: 497–510.
10.
FjellAMWalhovdKBFennema-NotestineC, et al.One-year brain atrophy evident in healthy aging. J Neurosci2009; 29: 15223–15231.
11.
WhitwellJLDicksonDWMurrayME, et al.Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol2012; 11: 868–877.
12.
BobinskiMde LeonMJWegielJ, et al.The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience2000; 95: 721–725.
13.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
14.
DuboisBFeldmanHHJacovaC, et al.Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol2010; 9: 1118–1127.
15.
JackCRPetersenRCXuYC, et al.Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol1998; 43: 303–310.
16.
ErtekinTAcerNKöseoğluE, et al.Total intracranial and lateral ventricle volumes measurement in Alzheimer's disease: a methodological study. J Clin Neurosci2016; 34: 133–139.
17.
WangDWangPBianX, et al.Elevated plasma levels of exosomal BACE1-AS combined with the volume and thickness of the right entorhinal cortex may serve as a biomarker for the detection of Alzheimer's disease. Mol Med Rep2020; 22: 227–238.
18.
HorínekDVarjassyováAHortJ. Magnetic resonance analysis of amygdalar volume in Alzheimer's disease. Curr Opin Psychiatry2007; 20: 273–277.
19.
de JongLWvan der HieleKVeerIM, et al.Strongly reduced volumes of putamen and thalamus in Alzheimer's disease: an MRI study. Brain2008; 131: 3277–3285.
20.
OuyangXChenKYaoL, et al.Simultaneous changes in gray matter volume and white matter fractional anisotropy in Alzheimer's disease revealed by multimodal CCA and joint ICA. Neuroscience2015; 301: 553–562.
21.
Garnier-CrussardABougachaSWirthM, et al.White matter hyperintensity topography in Alzheimer's disease and links to cognition. Alzheimers Dement2022; 18: 422–433.
22.
DaviesNMHolmesMVDavey SmithG. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ2018; 362: k601.
23.
SunBBChiouJTraylorM, et al.Plasma proteomic associations with genetics and health in the UK Biobank. Nature2023; 622: 329–338.
24.
McRaeAFMarioniREShahS, et al.Identification of 55,000 replicated DNA methylation QTL. Sci Rep2018; 8: 17605.
25.
ZhuZZhangFHuH, et al.Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet2016; 48: 481–487.
26.
BurgessSDanielRMButterworthAS, et al.Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways. Int J Epidemiol2015; 44: 484–495.
27.
VõsaUClaringbouldAWestraH-J, et al.Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet2021; 53: 1300–1310.
28.
QiTWuYFangH, et al.Genetic control of RNA splicing and its distinct role in complex trait variation. Nat Genet2022; 54: 1355–1363.
29.
WuYZengJZhangF, et al.Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. Nat Commun2018; 9: 918.
30.
QiTWuYZengJ, et al.Identifying gene targets for brain-related traits using transcriptomic and methylomic data from blood. Nat Commun2018; 9: 2282.
31.
FerkingstadESulemPAtlasonBA, et al.Large-scale integration of the plasma proteome with genetics and disease. Nat Genet2021; 53: 1712–1721.
32.
WingoAPLiuYGerasimovES, et al.Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer's disease pathogenesis. Nat Genet2021; 53: 143–146.
33.
YangCFariasFHGIbanezL, et al.Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nat Neurosci2021; 24: 1302–1312.
34.
BellenguezCKüçükaliFJansenIE, et al.New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet2022; 54: 412–436.
35.
BurgessSBowdenJFallT, et al.Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. Epidemiology2017; 28: 30–42.
36.
BowdenJDavey SmithGBurgessS. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. Int J Epidemiol2015; 44: 512–525.
37.
BowdenJDavey SmithGHaycockPC, et al.Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol2016; 40: 304–314.
38.
HartwigFPDavey SmithGBowdenJ. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol2017; 46: 1985–1998.
39.
BurgessSDavey SmithGDaviesNM, et al.Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res2019; 4: 186.
40.
BurgessSDudbridgeFThompsonSG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med2016; 35: 1880–1906.
41.
BurgessSButterworthAThompsonSG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol2013; 37: 658–665.
42.
BurgessSSmallDSThompsonSG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res2017; 26: 2333–2355.
43.
BowdenJDel GrecoMFMinelliC, et al.A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med2017; 36: 1783–1802.
44.
BowdenJDel GrecoMFMinelliC, et al.Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption. Int J Epidemiol2019; 48: 728–742.
45.
BurgessSThompsonSG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol2011; 40: 755–764.
46.
HemaniGTillingKDavey SmithG. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet2017; 13: e1007081.
47.
LealSM. Genetics and analysis of quantitative traits. Am J Hum Genet2001; 68: 548–549.
48.
LiuXLiCSunX, et al.Genetically predicted insomnia in relation to 14 cardiovascular conditions and 17 cardiometabolic risk factors: a Mendelian randomization study. J Am Heart Assoc2021; 10: e020187.
49.
de RojasIMoreno-GrauSTesiN, et al.Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nat Commun2021; 12: 3417.
50.
KyngKJMayAStevnsnerT, et al.Gene expression responses to DNA damage are altered in human aging and in Werner Syndrome. Oncogene2005; 24: 5026–5042.
51.
LombardoSMaskosU. Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment. Neuropharmacology2015; 96: 255–262.
52.
GottiCMorettiMBohrI, et al.Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis2006; 23: 481–489.
53.
AlbuquerqueEXPereiraEFRAlkondonM, et al.Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev2009; 89: 73–120.
54.
ParriHRHernandezCMDineleyKT. Research update: alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. Biochem Pharmacol2011; 82: 931–942.
55.
HernandezCMKayedRZhengH, et al.Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci2010; 30: 2442–2453.
56.
AroraKAlfulaijNHigaJK, et al.Impact of sustained exposure to β-amyloid on calcium homeostasis and neuronal integrity in model nerve cell system expressing α4β2 nicotinic acetylcholine receptors. J Biol Chem2013; 288: 11175–11190.
57.
CarmichaelOTKullerLHLopezOL, et al.Cerebral ventricular changes associated with transitions between normal cognitive function, mild cognitive impairment, and dementia. Alzheimer Dis Assoc Disord2007; 21: 14–24.
58.
Loc'hJDelarueM. Terminal deoxynucleotidyltransferase: the story of an untemplated DNA polymerase capable of DNA bridging and templated synthesis across strands. Curr Opin Struct Biol2018; 53: 22–31.
59.
MahajanKNNick McElhinnySAMitchellBS, et al.Association of DNA polymerase mu (pol mu) with ku and ligase IV: role for pol mu in end-joining double-strand break repair. Mol Cell Biol2002; 22: 5194–5202.
60.
MahajanKNGangi-PetersonLSorscherDH, et al.Association of terminal deoxynucleotidyl transferase with Ku. Proc Natl Acad Sci U S A1999; 96: 13926–13931.
61.
FengBZhengJCaiY, et al.An epigenetic manifestation of Alzheimer's disease: DNA methylation. Actas Esp Psiquiatr2024; 52: 365–374.
62.
De PlanoLMSaittaAOddoS, et al.Epigenetic changes in Alzheimer's disease: DNA methylation and histone modification. Cells2024; 13: 719.
63.
YardenYPinesG. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer2012; 12: 553–563.
64.
NyatiMKMorganMAFengFY, et al.Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer2006; 6: 876–885.
65.
LiccardiGHartleyJAHochhauserD. EGFR Nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res2011; 71: 1103–1114.
66.
LuZCuiMZhaoH, et al.Tissue kallikrein mediates neurite outgrowth through epidermal growth factor receptor and flotillin-2 pathway in vitro. Cell Signal2014; 26: 220–232.
67.
JayaswamyPKVijaykrishnarajMPatilP, et al.Implicative role of epidermal growth factor receptor and its associated signaling partners in the pathogenesis of Alzheimer's disease. Ageing Res Rev2023; 83: 101791.
68.
RomanoRBucciC. Role of EGFR in the nervous system. Cells2020; 9: 1887.
69.
MoralesCDCotton-SamuelDLaoPJ, et al.Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer's clinical trial participants. Alzheimers Res Ther2024; 16: 25.
70.
PietroboniAMColombiACarandiniT, et al.The role of amyloid-β in white matter damage: possible common pathogenetic mechanisms in neurodegenerative and demyelinating diseases. J Alzheimers Dis2020; 78: 13–22.
71.
ManczakMReddyPH. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum Mol Genet2012; 21: 5131–5146.
72.
CasoFAgostaFFilippiM. Insights into white matter damage in Alzheimer's disease: from postmortem to in vivo diffusion tensor MRI studies. Neurodegener Dis2016; 16: 26–33.
73.
NasrabadySERizviBGoldmanJE, et al.White matter changes in Alzheimer's disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun2018; 6: 22.
74.
RamírezESánchez-MaldonadoCMayoralMA, et al.Neuroinflammation induced by the peptide amyloid-β (25–35) increase the presence of galectin-3 in astrocytes and microglia and impairs spatial memory. Neuropeptides2019; 74: 11–23.
75.
SrejovicISelakovicDJovicicN, et al.Galectin-3: roles in neurodevelopment, neuroinflammation, and behavior. Biomolecules2020; 10: 798.
76.
YiH-AMöllerCDielemanN, et al.Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. J Neurol Neurosurg Psychiatry2016; 87: 425–432.
77.
XuerebJHPerryRHCandyJM, et al.Nerve cell loss in the thalamus in Alzheimer's disease and Parkinson's disease. Brain1991; 114: 1363–1379.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
